Kennedy Capital Management’s Myriad Genetics MYGN Stock Holding History

Kennedy Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-25,884	Closed	-$512K	–	693
2020 Q4	$512K	Buy	+25,884	New	+$418K	0.01%	585
2020 Q1	–	Sell	-98,244	Closed	-$2.67M	–	704
2019 Q4	$2.67M	Buy	+98,244	New	+$2.7M	0.07%	496
2019 Q1	–	Sell	-380,075	Closed	-$11M	–	705
2018 Q4	$11M	Buy	+380,075	New	+$13.7M	0.27%	84

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Kennedy Capital Management's MYGN Position: Q1 2021 in Review

Kennedy Capital Management sold out of Myriad Genetics (MYGN) in Q1 2021, closing a stake of 25,884 shares — an estimated $512K sold.

Kennedy Capital Management first reported a position in MYGN in Q4 2018 and held it in 3 quarters. The position peaked at $11M in Q4 2018. 197 funds tracked by Wall St. Rank hold MYGN as of Q1 2021.

Kennedy Capital Management reported no remaining Myriad Genetics position as of Q1 2021 after selling out during the quarter.
Kennedy Capital Management sold 25,884 Myriad Genetics shares in Q1 2021, an estimated $512K.
Kennedy Capital Management first reported a position in Myriad Genetics in Q4 2018 and held it in 3 quarters.
Kennedy Capital Management's Myriad Genetics position peaked at $11M in Q4 2018.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2021.

Based on Kennedy Capital Management's 13F filing for Q1 2021, filed 14 May 2021.